Highest-materiality recent filing
GT Biopharma enters agreement with Univ. of Minnesota for Phase 1a/1b trial of GTB-5550
Agreement for IND 169118 GTB-5550 (camB7-H3 TriKE) in advanced solid tumors that failed prior therapy.
GT Biopharma restates Q2/Q3 2025 financials; Greenshoe Rights liability misclassified
Audit committee concluded non-reliance on Q2 and Q3 2025 Form 10-Q after finding Greenshoe Rights should have been liability under ASC 480.
GT Biopharma receives Nasdaq delisting notice for low bid price
Nasdaq notified GT Biopharma on Nov 20, 2025 that stock closed below $1 for 30 consecutive days, violating Minimum Bid Price Requirement.
GT Biopharma stockholders approve share issuance for May 2025 financings and omnibus plan amendment
All four director nominees (Breen, Casamento, Kramer, Mun-Gavin) elected with 1.18M+ votes each, no votes under 14K.
On June 10, 2025, the Board appointed David C. Mun-Gavin as a non-employee director of the Board.
On June 9, 2025, Andrew Ritter resigned as a member of the board of directors (the “Board”) of the Company and all committees thereof.
Max materiality 0.90 · Median 0.55 · Most common event other_material